Human Longevity, Inc. has launched a new company, Human Life Foundation Models, Inc. (HLFM), which will focus on developing large-scale foundation models aimed at advancing human longevity science. This initiative includes a strategic partnership with Insilico Medicine, a leader in artificial intelligence for drug discovery, under a multi-year collaboration estimated to be worth millions. The global longevity market is projected to grow from approximately $5.3 trillion to nearly $8 trillion by 2030, highlighting the urgency of this endeavor. HLFM plans to integrate Human Longevity's vast datasets, which encompass genomics, imaging, and clinical data, with Insilico's advanced AI technologies to create predictive models for disease risk and aging biology. The collaboration is designed to respect patient privacy, ensuring that raw health data remains with its original custodians. By focusing on early disease detection and personalized interventions, HLFM and Insilico aim to transform healthcare from a reactive to a preventive model, potentially unlocking significant advancements in healthspan and longevity therapeutics.